These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 2320790

  • 1. [Pleural effusion induced by bromocriptine].
    Diot E, Diot P, Le Rolland A, Jonville AP, Lasfargues G, Lemarie E, Lavandier M, Guilmot JL.
    Rev Mal Respir; 1990; 7(2):175-7. PubMed ID: 2320790
    [Abstract] [Full Text] [Related]

  • 2. [Pleural effusion and constrictive pericarditis secondary to bromocriptine treatment].
    Saura J, Aguilar M, Alió J.
    Neurologia; 1991 Nov; 6(9):331-3. PubMed ID: 1809340
    [Abstract] [Full Text] [Related]

  • 3. [Diffuse interstitial lung disease without pleural involvement and high-dose bromocriptine].
    Marsaudon E, Castet D, Barrault MF, Allais C.
    Rev Mal Respir; 1997 Nov; 14(5):405-7. PubMed ID: 9480488
    [Abstract] [Full Text] [Related]

  • 4. [Bromocriptine in Parkinson's disease: pleuropulmonary toxicity].
    Douvier JJ, Vergeret J, Taytard A, Brottier E, Domblides P, Dubos F, Freour P.
    Ann Med Interne (Paris); 1985 Nov; 136(5):416-8. PubMed ID: 4062141
    [Abstract] [Full Text] [Related]

  • 5. [Pleural effusion and severe edema of the lower limbs induced by bromocriptine].
    Messiaen T, Lefebvre C, Weynand B, Pieters T.
    Rev Med Interne; 1996 Nov; 17(8):680-3. PubMed ID: 8881198
    [Abstract] [Full Text] [Related]

  • 6. [Pleuropneumopathy caused by bromocriptine in a patient with Parkinson disease. Review of the literature apropos of a new case].
    Debove P, Simon F, Vaylet F, Renard JL, L'Her P.
    Ann Med Interne (Paris); 1998 Apr; 149(3):167-71. PubMed ID: 11490541
    [Abstract] [Full Text] [Related]

  • 7. Pleuropulmonary involvement during bromocriptine treatment.
    Kinnunen E, Viljanen A.
    Chest; 1988 Nov; 94(5):1034-6. PubMed ID: 3180854
    [Abstract] [Full Text] [Related]

  • 8. [Pleuropulmonary fibrosis and bromocriptine].
    Vergeret J, Barat M, Taytard A, Bellvert P, Domblides P, Douvier JJ, Fréour P.
    Sem Hop; 1984 Mar 08; 60(11):741-4. PubMed ID: 6324351
    [Abstract] [Full Text] [Related]

  • 9. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease.
    Lancet; 1981 Jan 03; 1(8210):44-5. PubMed ID: 6109080
    [No Abstract] [Full Text] [Related]

  • 10. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
    Frans E, Dom R, Demedts M.
    Eur Respir J; 1992 Feb 03; 5(2):263-5. PubMed ID: 1348483
    [Abstract] [Full Text] [Related]

  • 11. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
    Rascol A, Montastruc JL, Guiraud-Chaumeil B, Clanet M.
    Rev Neurol (Paris); 1982 Feb 03; 138(5):401-8. PubMed ID: 7146724
    [Abstract] [Full Text] [Related]

  • 12. Long-term treatment with high-dosage bromocriptine in advanced Parkinson's disease.
    Jansen EN, Meerwaldt JD.
    Adv Neurol; 1987 Feb 03; 45():539-42. PubMed ID: 3103396
    [Abstract] [Full Text] [Related]

  • 13. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD, Delgado MR.
    Clin Neuropharmacol; 1985 Feb 03; 8(1):73-7. PubMed ID: 3978651
    [Abstract] [Full Text] [Related]

  • 14. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease.
    Stern GM, Lees AJ.
    Adv Neurol; 1983 Feb 03; 37():17-21. PubMed ID: 6858771
    [Abstract] [Full Text] [Related]

  • 15. [Bromocriptine-induced pleuropneumopathy].
    Schmid PA, Suter T, Speich R, Eberli F, Greminger P.
    Dtsch Med Wochenschr; 1994 Nov 11; 119(45):1543-6. PubMed ID: 7956789
    [Abstract] [Full Text] [Related]

  • 16. Pleuropulmonary reactions in patients on bromocriptine treatment.
    Tornling G, Unge G, Axelsson G, Noring L, Granerus AK.
    Eur J Respir Dis; 1986 Jan 11; 68(1):35-8. PubMed ID: 3948932
    [Abstract] [Full Text] [Related]

  • 17. Dopamine agonists in the treatment of Parkinson's disease.
    Rinne UK.
    Adv Neurol; 1983 Jan 11; 37():141-50. PubMed ID: 6305175
    [Abstract] [Full Text] [Related]

  • 18. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
    Kim JY, Chung EJ, Park SW, Lee WY.
    Mov Disord; 2006 Aug 11; 21(8):1261-4. PubMed ID: 16685692
    [Abstract] [Full Text] [Related]

  • 19. [Bromocriptine and pulmonary responses].
    Kinnunen E, Viljanen A.
    Duodecim; 1989 Aug 11; 105(19):1614-7. PubMed ID: 2806146
    [No Abstract] [Full Text] [Related]

  • 20. [Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease].
    Sánchez-Chapado M, Angulo Cuesta J, Guil Cid M, Jiménez FJ, López Alvarez YJ.
    Arch Esp Urol; 1995 Dec 11; 48(10):979-83. PubMed ID: 8588730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.